Tag: presentation
Company News: Anergis to Present Three Scientific Posters at 34th European Academy of Allergy and Clinical Immunology (EAACI) Congress 2015
Anergis, a company developing novel and proprietary ultra-fast allergy immunotherapeutics, will present three scientific posters at the 34th European Academy of Allergy and Clinical Immunology (EAACI) Congress 2015 (Barcelona, June 6-10, 2015). All posters will focus on Anergis´ birch pollen immunotherapeutic AllerT, featuring detailed clinical data as well as in vitro and in vivo safety and immunogenicity data. AllerT is Anergis´ most advanced product and based on the company´s proprietary Contiguous Overlapping Peptide (COP) platform.
The following scientific communications will be presented at the EAACI Conference 2015:
Presentation Title: “Phase IIb follow-up trial of sustained efficacy of AllerT allergy vaccine during a second birch pollen season”
Presenter: Gilles Della Corte
Time and Date: Sunday, June 7, 2015, at 02:06pm CET
Session: Oral Abstract Session OAS 10 AIT: Efficacy and clinical outcomes
Abstract #: 327
Presentation Title: “Persistence of anti-Bet v 1 IgG4 prior and during a second pollen season after AllerT ultra-fast immunotherapy (phase IIb follow up)”
Presenter: Dr. Christophe Reymond
Time and Date: Tuesday, June 9, 2015, at 10:30am CET
Session: Poster Discussion Session PDS 25: Immunotherapy vaccines
Abstract #: 530
Presentation Title: “Requirement for aluminium hydroxide as adjuvant for successful ultra-fast immunotherapy with AllerT”
Presenter: Dr. Alexander Kettner
Time and Date: Monday, June 8, 2015, at 12:00pm CET
Session: Thematic Poster Session TPS 32: Allergen standardization
Abstract #: 1141
Company News: Anergis to Present New COP Allergy Vaccine Data at EAACI Conference 2014 in Copenhagen
– Four scientific communications scheduled for June 8, 9 and 10, 2014 –
Anergis, a company discovering and developing proprietary allergy vaccines, today announced it will present four scientific communications on its Contiguous Overlapping Peptides (COP) allergy vaccines at this year’s European Academy of Allergy and Clinical Immunology Congress 2014 (EAACI) in Copenhagen, Denmark. The presentations focus on Anergis´ lead compound AllerT against birch pollen allergies, its house dust mite vaccine candidate AllerDM, and a general economic evaluation of allergen immunotherapy for seasonal allergies.
The following scientific communications will be presented at the EAACI Conference 2014:
Presentation Title: “AllerT™, Safety and efficacy of a birch pollen allergy vaccine based on contiguous overlapping peptides in a phase IIb study”
Presenter: Prof. Dr. Marek Jutel
Time and Date: Sunday, June 8, 2014, at 03:30pm CET
Session: Oral Abstract Session OAS12: Novel Vaccines for AIT
Abstract #: 481
Presentation Title: “Development of a hypoallergenic formulation for immunotherapy against house dust mite allergy based on Contiguous Overlapping Peptides”
Presenter: Dr. Alexander Kettner
Time and Date: Monday, June 9, 2014, at 03:45pm CET
Session: Poster Discussion Session PDS 12: AIT Mechanisms
Abstract #: 347
Presentation Title: “Effect of AllerT™ ultra-fast immunotherapy on Bet v 1 specific IgG4 and IgE levels; results from a phase IIb study”
Presenter: Prof. Dr. Christophe Reymond
Time and Date: Monday, June 9, 2014, at 03:45pm CET
Session: Poster Discussion Session PDS 12: AIT Mechanisms
Abstract #: 559
Presentation Title: “Economic evaluation of allergen immunotherapy for seasonal allergic rhinitis”
Presenter: Jean-Paul Rohmer
Time and Date: Tuesday, June 10, 2014, at 12:00pm CET
Session: Thematic Poster Session TPS64: Immunotherapy – AIT Clinics IV
Abstract #: 1411
Company News: New Clinical Data Demonstrate Strong Synergy between Cancer Vaccine ISA101 and Chemotherapy
– Data presented at the AACR Annual Meeting 2014
– Potential new treatment being developed for patients with late-stage cervical cancer
ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed therapeutic vaccines against cancer and persistent viral infections, has announced new clinical data on its lead product candidate ISA101. ISA101 is a therapeutic cancer vaccine for the treatment of high-risk, HPV16-induced diseases, such as cervical cancer. The data were presented by principal investigator Prof. Sjoerd van der Burg, Ph.D., at this year’s American Association for Cancer Research (AACR) Annual Meeting in San Diego.
The data demonstrate strong synergy between ISA101 and chemotherapy, offering potential new treatment options for cervical cancer patients scheduled to receive standard chemotherapy with carboplatin / paclitaxel.
Prof. van der Burg and his group evaluated the immunological and clinical responses of patients with advanced cervical carcinoma in a Phase I combination trial. In this pilot trial, patients received ISA101 in combination with standard chemotherapy cycles (carboplatin / paclitaxel). Almost all patients showed a strong immune response to the ISA101 vaccine. Comprehensive immune monitoring confirmed the beneficial effect of myeloid suppressor cell depletion associated with a robust induction of HPV16-specific T-cell responses that were sustained throughout several cycles of chemotherapy.
The observation that depletion of myeloid suppressor cells by a carboplatin/paclitaxel chemotherapy regimen enhances the immune response to ISA101 is in line with prior observations that tumors promote immune tolerance starting early in the disease and that chemotherapy can restore immune competence in cancer patients.
Based on these results ISA has initiated a phase I/II study (CervISA) in October last year testing ISA101 in combination with carboplatin, paclitaxel and pegylated interferon alpha in women with advanced or recurrent cervical cancer.
The presentation titled “Synergistic effects of properly timed HPV16 SLP vaccination during standard carboplatin-paclitaxel chemotherapy in animals and patients with metastatic cervical carcinoma“ was given at the Minisymposium MS.IM02.01 “Immune-based Therapies: Responses, Biomarkers, and Mechanisms” on Monday, April 07, 2014, at 3:20 PM in Room 6CF at the San Diego Convention Center.
The abstract # 2938 is available at the AACR website www.aacr.org.
Company News: New Clinical Data on Cancer Vaccine ISA101 to Be Presented at the AACR Annual Meeting 2014
ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed therapeutic vaccines against cancer and persistent viral infections, today announced that principal investigator Prof. Sjoerd van der Burg, Ph.D., will present new clinical data on ISA101 at this year’s American Association for Cancer Research (AACR) Annual Meeting. ISA101 is a therapeutic cancer vaccine for the treatment of high-risk, HPV16-induced diseases.
The presentation titled “Synergistic effects of properly timed HPV16 SLP vaccination during standard carboplatin-paclitaxel chemotherapy in animals and patients with metastatic cervical carcinoma“ will be given at the Minisymposium MS.IM02.01 “Immune-based Therapies: Responses, Biomarkers, and Mechanisms” on Monday, April 07, 2014, at 3:20 PM in Room 6CF at the San Diego Convention Center.
The abstract # 2938 is available at the AACR website www.aacr.org.